The public-private partnership distributing the COVID vaccines is in the starting blocks. Planning is almost done. Now it’s time to execute the race once the FDA says the drugs are safe for public use.
While the entire pharmaceutical supply chain is focused on distributing a COVID vaccine, the stresses it is putting on other areas of the chain are growing.
How do you prepare for the Super Bowl if you don’t know who your opponent is? That’s how airlines and freight managers feel about preparations for transporting a COVID-19 vaccine when one is approved because manufacturers aren’t freely sharing shipping details.
Informed pharmaceutical transportation means higher success.
New medicines and life science products are more valuable and temperature-sensitive than before, requiring special storage and transportation conditions. Will there be enough of this infrastructure to handle a COVID vaccine?
Whether or not President Donald Trump’s optimism about an October surprise comes to fruition, there could be an approved coronavirus vaccine next year. A giant flotilla of all-cargo planes will be deployed to deliver the medicine around the world, but airlines are already short of capacity and there isn’t yet enough refrigerated infrastructure to safely store that much vaccine. Airlines are issuing a call to action.
Lufthansa is expanding its network of cold storage facilities for pharmaceutical products. The network meets the highest industry standards.
Drone technology provider to UPS Flight Forward aims for unmanned aircraft systems certification from the U.S. Federal Aviation Administration.
Marken has acquired three European companies based out of central and eastern Europe, to expand its geographic footprint in the pharma and life science logistics segments.
